A study in Diabetes Care found that patients with type 2 diabetes and COVID-19 who took a combination of sitagliptin and insulin had an 18% mortality rate, compared with a 37% mortality rate among those who only took insulin. The findings also revealed that the group who took both sitagliptin and insulin had lower odds of requiring mechanical ventilation and intensive care, and were less likely to have a worsening of clinical outcomes, compared with the group who only took insulin.
Sitagliptin tied to lower mortality in T2D, COVID-19
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.